Anti-Human CD283 (TLR3) PE

Grouped product items
Size Price Qty
25 ug
$340.00
100 ug
$595.00

Additional TLR3.7 Formats

Cat.No. Format Starting From
25911-60 PE $ 340.00
Catalog Number : 25911-60

description

The TLR3.7 monoclonal antibody specifically reacts with human CD283 (TLR3), a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain. It is expressed by dendritic cells and recognize double-stranded RNA and polyinosine-polycytidylic acid. Upon ligand binding, CD283 induces type I interferon production and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells complex (NF-κB).

Additional Information

Clone:
TLR3.7
Format:
PE
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest: Innate Immunity
Cell Type: Dendritic Cells
Application: FC
Clone: TLR3.7
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K., & Seya, T. (2002). Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochemical and biophysical research communications293(5), 1364-1369.

Schreiner, B., Voss, J., Wischhusen, J., Dombrowski, Y., Steinle, A., Lochmüller, H., ... & Wiendl, H. (2006). Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. The FASEB journal20(1), 118-120.

Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., & Seya, T. (2003). TICAM-1, an adaptor molecule that participates in Toll-like receptor 3–mediated interferon-β induction. Nature immunology4(2), 161-167.

© BioGems International, Inc. All rights reserved.